Ligand (LGND) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$290.5M

Revenue (quarter)

$63.7M

Revenue growth (year over year)

+33.73%

Gross profit (trailing twelve months)

$277.3M

Gross margin

95.43%

Net income (trailing twelve months)

$197.2M

Net income (quarter)

$48.5M

Net income growth (year over year)

+900.78%

Net margin

67.88%

Return on equity

21.96%

EPS (trailing twelve months)

$10.15

Book value per share

$48.57

P/E (trailing twelve months)

30.14

Price to book

6.14

Debt to assets

55.74%

Payout ratio

−85.80%

Dividend yield

—

Company profile

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

• Is Ligand (LGND) profitable?

  Yes. Ligand earned $197.2M in net income over the trailing twelve months, a net margin of 67.88%.

• How much revenue does Ligand (LGND) make?

  Ligand generated $290.5M in revenue over the trailing twelve months, up 33.73% year over year.

• What is LGND's P/E ratio?

  Ligand trades at 30.1 times trailing twelve-month earnings, on an EPS of $10.15.

• How do I buy stock in Ligand (LGND)?

  LGND trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.